IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1642		
Martin Leonard Ashdown	Confirmation No.: 8112		
Serial No.: 10/576,981) Examiner: Mark Halvorson		
Filed: March 2, 2007)		
Atty. File No.: 5517-18	SUPPLEMENTAL) INFORMATION DISCLOSURE		
Entitled: "Method of Therapy") INFORMATION DISCLOSURE STATEMENT		
) Electronically Submitted		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
Dear Sir:			
The references cited on attached Form PTC	0-1449 are being called to the attention		
of the Examiner.			
Copies of the cited non-patent and/or foreign references are enclosed herewith.			
Copies of the cited U.S. patents and/or paten	Copies of the cited U.S. patents and/or patent applications are enclosed herewith.		
Copies of the cited U.S. patents/patent appli	cation publications are not enclosed in		
accordance with 37 C.F.R. § 1.98(a).			
Copies of the cited references are not enclosed, in accordance with 37 C.F.R.			
§ 1.98(d), because the references were cited by			
Trademark Office in prior application Serial No	, filed,		
which is relied upon for an earlier filing date under	35 U.S.C. § 120.		
To the best of applicants' belief, the pertine	ence of the foreign-language references		
are believed to be summarized in the attached E	nglish abstracts and/or in the figures,		
although applicants do not necessarily vouch for the	accuracy of the translation.		
Examiner's attention is drawn to the following	ng related applications:		
Serial No filed	(Attorney Ref. No)		
Serial No filed	(Attorney Ref. No)		
Other:			
Submission of the above information is not i	ntended as an admission that any item		
is citable under the statutes or rules to support a reje	ction, that any item disclosed		
represents analogous art, or that those skilled in the	art would refer to or recognize the		
pertinence of any reference without the benefit of hindsight, nor should an inference be			

drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfied by one of the following conditions ("X" indicates satisfaction): Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application, or Before the mailing date of a first Office Action on the merits, or Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.	
37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of any one of the following conditions: (1) a final action under 37 C.F.R. 1.113, or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by: A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.	
37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c). This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.	

		ion (37 C.F.R. 1.97(e)) able only if checked)
	first cited in any communic application not more than the 1.97(e)(1).	on contained in this information disclosure statement wa ation from a foreign patent office in a counterpart foreig aree months prior to the filing of this statement. 37 C.F.R communication from the foreign patent office is enclosed.
		OR
	cited in a communication from application, and, to the known inquiry, no item of informat	contained in this information disclosure statement was om a foreign patent office in a counterpart foreign yledge of the undersigned after making reasonable ion contained in this Information Disclosure Statement I designated in 37 C.F.R. 1.56(c) more than three months ement. 37 C.F.R. 1.97(e)(2).
		Respectfully submitted,
		SHERIDAN ROSS P.C.
Date:	10/10/2011	By: Robert D. Traver Ph.D. Reg. No. 47999 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141 (303) 863-9700

Date: 10/10/2011